 "Alembic receives US FDA approval for gout drug febuxostat")
Alembic Pharmaceuticals Ltd has received tentative approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for febuxostat tablets - 40 mg and 80 mg. The approved product is generic equivalent of Takeda Pharmaceuticals USA Inc's Uloric tablets, used for treating chronic management of hyperuricemia in patients with gout.
Alembic has settled the case with Takeda and will launch its generic as per the terms of the settlement.
Uloric has an estimated market size of $ 430 million for twelve months ending December 2015, according to IMS.
Alembic now has a total of 48 ANDA approvals (43 final approvals and 5 tentative approvals) from the US FDA.
Alembic has settled the case with Takeda and will launch its generic as per the terms of the settlement.
Uloric has an estimated market size of $ 430 million for twelve months ending December 2015, according to IMS.
Alembic now has a total of 48 ANDA approvals (43 final approvals and 5 tentative approvals) from the US FDA.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%